AZYO

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 23, 2022

AZIYO BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

12510 Prosperity Drive, Suite 370
Silver Spring, MD 20904 

(Address of principal executive offices) (Zip Code)

(240) 247-1170 

(Registrant’s telephone number, include area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

On December 23, 2022, Aziyo Biologics, Inc. (the “Company”) entered into an Amended and Restated Employment Agreement (each, an “Amended and Restated Employment Agreement”) with each of the following of the Company’s named executive officers: Matthew Ferguson, Chief Financial Officer, and Thomas Englese, Chief Commercial Officer. Each Amended and Restated Employment Agreement amends such executive’s respective employment agreement, dated as of September 30, 2020 (each, the “Employment Agreement”), to provide that the term of the executive’s employment under his Employment Agreement, which had an initial term of two years, subject to an automatic extension for an additional one-year period unless the Company or the executive gave notice of non-extension, commences as of the date of the Amended and Restated Employment Agreement and ends on the date that the Amended and Restated Employment Agreement is terminated in accordance with the termination provisions thereunder. There were no other changes to the terms of such executive’s Employment Agreement, each of which has been previously filed with the Securities and Exchange Commission.

The forgoing descriptions of the Amended and Restated Employment Agreements do not purport to be complete and are qualified in their entirety by reference to the text of the Amended and Restated Employment Agreements, copies of which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

(d) Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From May 2023 to Jun 2023

Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Jun 2022 to Jun 2023